ENx209

ENx209 is a preclinical investigational biologic being developed by Enleofen Bio as part of a pipeline of interleukin‑11 (IL‑11) pathway inhibitors targeting fibrotic and inflammatory diseases across multiple organs.[9] Publicly available information identifies ENx209 only as a follow‑on or additional IL‑11–targeting therapeutic candidate alongside ENx108A and ENx203, without disclosing its precise molecular format, target epitope, or lead indications.[9] IL‑11 is a profibrotic cytokine, and genetic and pharmacologic blockade of IL‑11 or its receptor has been shown in preclinical models to reverse or prevent organ dysfunction in liver, lung, kidney, cardiac, and other tissues, supporting ENx209’s development as an anti‑fibrotic, anti‑inflammatory therapy.[7][9][10][15]

Other names

EnX209EnX-209EnX 209